BioLeap > Collaborations

Overview

Lead generation is a time-consuming and inefficient process with an ever-increasing failure rate. Here is a typical example of current lead-generation methods using high-throughput screening (HTS):

BioLeap solves this problem by delivering custom-made pre-clinical drug leads and candidates, in collaboration or as a service. Enabled by computational fragment-based methods, we design compounds of unrestricted chemical diversity that bind to their target with predictable affinities. By minimizing unproductive guesswork, we achieve pre-clinical milestones in shorter times and provide better value compared to current methods.

BioLeap’s process quickly identifies lead compounds without the expensive infrastructure required for HTS and experimental fragment-based approaches. It also eliminates unproductive chemical synthesis during lead optimization. BioLeap’s approach is a surgical strike.